Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
2-Year U.S. Treasury Note Continuous Contract $102.832 0.074 0.07% 5-Year U.S. Treasury Note Continuous Contract $106.531 0.141 0.13% 10-Year U.S. Treasury Note Continuous Contract $109.141 0.188 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback